Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatamide Combined With Maximal Tumor Eradication for Oligometastatic Prostate Cancer, A Prospective Randomized Controlled Trial

NCT06972511 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06972511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06972511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatamide Combined With Maximal Tumor Eradication for Oligometastatic Prostate Cancer, A Prospective Randomized Controlled Trial
Lead sponsor
RenJi Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 20, 2023
Completion date
December 30, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic prostate cancer